VMD — Viemed Healthcare, Inc.

Viemed Healthcare, Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: $75.4 million, a 28% increase year-over-year; flat compared to Q4 2025.
• Gross Profit: $42.8 million, margin of 56.8%, slightly improved from 56.3% in 2025 but down from 57.9% in Q4 2025.
• Adjusted EBITDA: $14.3 million (19% of revenue), compared to $12.8 million (21.6% of revenue) in 2025; adjusted for a prior-year gain, the margin reflects a 200 basis point improvement.
• Net Income: $2.6 million, or $0.06 per diluted share, flat compared to the previous year.
• Free Cash Flow: Improved to $2.6 million from a negative $5.7 million in 2025, reflecting stronger operational cash generation and reduced capital expenditures.
• Net CapEx: $5.5 million, down from $8.5 million in 2025; updated full-year outlook to 9% - 10.5% of net revenue.

2. Strategic Updates and Business Highlights:

• Sleep Business: Continued strong growth with PAP therapy patients increasing by 57% year-over-year, totaling nearly 36,000 patients.
• Maternal Health: Integration of Lehan business exceeded expectations, servicing nearly 4,000 new patients in previously unserved markets.
• Ventilation: New patient startup momentum is strong, with March showing 759 setups, up from 692 a year ago; compliance rates have improved by nearly 20% since new NCD criteria were implemented.
• Diversification: Revenue mix is shifting away from ventilator rentals (47% of total revenue) towards sleep and maternal health, reducing concentration risk and improving capital efficiency.

3. Forward Guidance and Outlook:

• Revenue Guidance: Updated to a range of $312 million to $320 million for 2026, with adjusted EBITDA reaffirmed at $65 million to $69 million.
• Sequential Growth Expectation: Anticipated revenue growth of 3% to 5% per quarter for the remainder of the year, supported by strong operational signals in ventilation and maternal health.

4. Challenges and Points of Concern:

• Ventilation Compliance Dynamics: While new patient starts are strong, compliance issues related to the new NCD criteria are creating near-term pressure on patient census, which ended at 12,089.
• Operational Challenges: The need for back-office and fulfillment staffing to support rapid growth in maternal health could be a limiting factor.
• Regulatory Environment: Ongoing advocacy for policy changes regarding compliance interruptions that could affect patient access to ventilation therapy.

5. Notable Q&A Insights:

• Revenue Upside Potential: Management indicated that all product lines (ventilation, maternal health, sleep) have the potential to contribute to revenue upside, with maternal health showing particularly strong growth.
• Operational Efficiency: There is ongoing focus on improving efficiencies, particularly through AI and machine learning, to enhance logistics and intake processes.
• Sales and Staffing: While hiring sales personnel is manageable, the focus is on scaling back-office operations to meet demand effectively.

Overall, Viemed Healthcare, Inc. demonstrated strong financial performance in Q1 2026, with significant growth in key business segments and a positive outlook for the remainder of the year, despite facing some compliance and operational challenges.